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Abstract
Recent studies have suggested that antithrombin (AT) could act as a significant physiologic regulator of FVIIa. However,
in vitro studies showed that AT could inhibit FVIIa effectively only when it was bound to tissue factor (TF). Circulating blood
is known to contain only traces of TF, at best. FVIIa also binds endothelial cell protein C receptor (EPCR), but the role of EPCR
on FVIIa inactivation by AT is unknown. The present study was designed to investigate the role of TF and EPCR in
inactivation of FVIIa by AT in vivo. Low human TF mice (low TF, ,1% expression of the mouse TF level) and high human TF
mice (HTF, ,100% of the mouse TF level) were injected with human rFVIIa (120 mg kg21 body weight) via the tail vein. At
varying time intervals following rFVIIa administration, blood was collected to measure FVIIa-AT complex and rFVIIa antigen
levels in the plasma. Despite the large difference in TF expression in the mice, HTF mice generated only 40–50% more of
FVIIa-AT complex as compared to low TF mice. Increasing the concentration of TF in vivo in HTF mice by LPS injection
increased the levels of FVIIa-AT complexes by about 25%. No significant differences were found in FVIIa-AT levels among
wild-type, EPCR-deficient, and EPCR-overexpressing mice. The levels of FVIIa-AT complex formed in vitro and ex vivo were
much lower than that was found in vivo. In summary, our results suggest that traces of TF that may be present in circulating
blood or extravascular TF that is transiently exposed during normal vessel damage contributes to inactivation of FVIIa by AT
in circulation. However, TF’s role in AT inactivation of FVIIa appears to be minor and other factor(s) present in plasma, on
blood cells or vascular endothelium may play a predominant role in this process.
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Introduction
Tissue factor pathway inhibitor (TFPI) is the primary physio-
logical regulator of factor VIIa (FVIIa)-tissue factor (TF)-induced
blood coagulation [1,2]. Although antithrombin III (AT) was
shown to inhibit FVIIa [3–6], the physiological significance of this
inhibition was debatable [7,8]. AT could effectively inhibit FVIIa
only when it was bound to TF and not free FVIIa [3,4]. Still,
compared to TFPI, AT was a poor inhibitor of FVIIa-TF [5,8,9].
Interestingly, Smith et al. [10] showed that levels of FVIIa-AT
complex were surprisingly abundant in plasma (2% of plasma
FVII antigen), and suggested that AT could be a significant
regulator of FVIIa function and turnover in plasma. Recently,
Agerso et al. [11] showed that rFVIIa-AT complex formation was
responsible for 65% of the total rFVIIa clotting activity clearance
following intravenous administration of rFVIIa in hemophilia
patients. This is somewhat surprising as in vitro studies showed
little inhibition of FVIIa by AT in the absence of TF, even in the
presence of saturating concentrations of heparin [3,4]. Further-
more, circulating blood contains either no detectable TF, or at
best, traces of TF [12–14]. The above studies raise an interesting
question that whether TF, either circulating or intravascular, or
some other factors in blood are responsible for relatively rapid
inactivation of FVIIa by AT in vivo.
Since AT preferentially inhibits FVIIa bound to TF, and FVIIa-
AT complex rapidly disassociates from TF [9], the circulating
levels of FVIIa-AT complex is thought to be an important indirect
indicator of intravascular TF exposure in vivo [10]. Therefore, a
number of recent studies measured plasma FVIIa-AT levels in
various patient groups to investigate whether FVIIa-AT levels in
plasma could predict hypercoagulable state and thrombotic risk
[15–18]. Although these studies indicate that the FVIIa-AT levels
may be useful in identifying hypercoagulable state in specific
patient groups, they strongly suggest that large prospective cohort
studies were needed to consider the clinical application of FVIIa-
AT complex determination [17]. More importantly, to date, there
is no empirical data in the literature showing that exposure of
blood to intravascular TF is primarily responsible for the
generation of FVIIa-AT complex in vivo.
Studies from our laboratory [19] and others [20,21] have
established that FVIIa binds endothelial protein C receptor
(EPCR) in a true ligand manner. The interaction between FVIIa
and EPCR is capable of not only eliciting protease activated
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receptor-1 (PAR1)-mediated barrier protective signaling [22,23],
but also promotes internalization of the receptor–ligand complex
[24]. At present, it is unknown whether FVIIa binding to EPCR
influences AT inactivation of FVIIa. Recently, we have shown that
rFVIIa administered to mice intravenously (i.v) associates with
EPCR, and EPCR facilitates the entry of FVIIa from circulation
into perivascular tissues [25]. Once entered into perivascular
tissues, FVIIa was retained there in functionally active state for
extended time periods (24 h to 7 days) [25], which sharply
contrasts to the short circulating half-life (,30 min) of FVIIa [26].
Since EPCR is present primarily on the endothelium whereas TF
is mainly localized in extravascular cells, it raises the possibility
that TF may be involved in FVIIa retention in extravascular
tissues.
Development of transgenic mice that express either low levels of
human TF (low TF) or high levels of human TF (HTF) in place of
murine TF were useful in obtaining valuable insights into TF’s role
in hemostasis, thrombosis and vascular development [27,28].
Compared to wild-type TF, low TF mice express ,1% of TF [29]
whereas HTF mice express ,100% of TF, except in the heart
[30]. Similarly, development of EPCR-deficient and EPCR-
overexpressing mice helped in elucidating the role of EPCR in
hemostasis and inflammation [31,32]. In the present study, we
used the above mice to investigate the role of TF and EPCR in
generation of FVIIa-AT complex in vivo. In order to compare the
rates of AT inactivation of FVIIa in vitro, ex vivo and in vivo,
human rFVIIa was administered to mice, or added to whole blood
or plasma. Evaluation of the role of TF and EPCR in AT
inactivation of exogenously administered rFVIIa is clinically
relevant as AT was believed to be primarily responsible for rapid
inactivation of therapeutically administered rFVIIa to hemophilic
patients [11]. In addition, we also measured endogenous levels of
FVIIa-AT complex in wild-type, TF and EPCR transgenic mice.
Materials and Methods
Ethics statement
Human participants: Blood from healthy donors was obtained
following a written consent. Human subject research was
approved by the Institutional Review Board at The University
of Texas Health Science Center at Tyler.
Animals: All studies involving animals were conducted in
accordance with the animal welfare guidelines set forth in the
Guide for the Care and Use of Laboratory Animals and
Department of Health and Human Services, and approved by
the Institutional Animal Use and Care Committee of The
University of Texas Health Science Center at Tyler, Tyler, TX
(Animal Welfare Assurance Number A3589-01; Protocol Number:
530).
Reagents
Human rFVIIa was obtained from Novo Nordisk A/S
(Maaloev, Denmark). Mouse rFVIIa was provided by Mirella
Ezban/Lars Petersen, Novo Nordisk (Denmark). Affinity purified
polyclonal antibodies against human FVIIa were provided by the
late Walter Kisiel (University of New Mexico, Albuquerque, NM,
USA). Murine FVIIa antibodies were raised in-house by
immunizing rabbits with recombinant mouse FVIIa. Antithrom-
bin and sheep anti-AT antibodies, for both human and murine,
were purchased from Haematologic Technologies, Inc (Essex
Junction VT, USA). Human factor X was from Enzyme Research
Laboratories (South Bend, IN, USA). Chromogenic substrate
Chromogenix S-2765 was from DiaPharma (West Chester, OH,
USA). Rat anti-mouse TF mAb (1H1) antibodies were provided by
Daniel Kirchhofer, Genentech, CA, USA. Donkey anti-sheep
biotinylated IgG was obtained from Thermo Scientific (Rockford,
IL, USA). Lipopolysaccharide (LPS) from Escherichia coli 0111:B4
were from Sigma (St. Louis. MO, USA). Streptavidin alkaline
phosphatase (ALP) and BluePhos microwell phosphatase substrate
system were from KPL (Gaithersburg, MD, USA).
Cells
Primary human umbilical vein endothelial cells (HUVEC),
EBM-2 basal medium, and growth supplements were purchased
from Lonza (Walkersville, MD, USA). Endothelial cells were
cultured in EBM-2 basal medium supplemented with growth
supplements, 1% penicillin/streptomycin, and 2% fetal bovine
serum.
Mice
The generation of low TF and HTF mice was described earlier
[29,30]. Breeding pairs of EPCR-deficient (EPCR-def) and EPCR-
overexpressing (EPCR-OE) mice were obtained from Chuck
Esmon (Oklahoma Medical Research Foundation, Oklahoma
City, OK, USA), and their generation was described in earlier
reports [31,32]. Where available, littermate controls were used as
wild-type mice. Otherwise, wild-type mice were obtained from
Jackson Laboratory (Bar Harbor, ME, USA) or in-house breeding
program. All mice were in C57BL/6J genetic background.
Administration of rFVIIa to mice, collection of blood and
tissues
Human rFVIIa was administered to mice via the tail vein at a
dose of 120 mg kg21 body weight in 100 mL of Tris-buffered saline
(TBS, 50 mM Tris–HCl, 0.15 M NaCl, pH 7.5). At various time
intervals, ranging from 5 min to 7 days after rFVIIa administra-
tion, blood was collected either via submandibular vein or by
cardiac puncture at right ventricle if it was a terminal time point.
Only two or three blood samples were obtained from each mouse.
Blood was collected into 1/10 volume of 0.13 M sodium citrate
anticoagulant unless otherwise specified. Mice were subsequently
exsanguinated by severing the renal artery and perfused by
flushing ice-cold saline containing 5 mM CaCl2+1 mM MgCl2
through the heart. Knee bone joints were excised, rinsed briefly
with ice-cold saline containing 5 mM CaCl2+1 mM MgCl2, and
then processed for measuring FVIIa activity and antigen levels.
Briefly, excised knee bone joints were cut into fine pieces with a
sharp razor blade, and added to TBS buffer containing EDTA
(20 mM) (0.5 mL buffer per 100 mg tissue), freeze-thawed,
vortexed, and centrifuged to obtain clear supernatant for
measuring FVIIa antigen or activity levels.
Ex vivo studies were conducted using blood drawn into factor
Xa inhibitor, rivaroxaban (100 mg/ml blood) as an anticoagulant.
Plasma was separated by centrifugation at 6, 0006g for 15 min.
Isolation of microparticles (MPs) from plasma, and TF
activity assay
Microparticles from mouse plasma were isolated essentially as
described earlier [33]. TF activity in MPs was measured by adding
either mouse (in wild-type mice) or human FVIIa (in low TF and
HTF mice) (10 nM), and human FX (175 nM), and measuring the
amount of FXa generated at the end of 1 or 2 h activation period
in a chromogenic assay. In some experiments, TF activity was
measured both in the presence and absence of neutralizing TF
antibodies to determine TF-specific coagulant activity.
Antithrombin Inactivation of Factor VIIa
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Generation and isolation of cell-derived microparticles
Confluent monolayers of HUVEC cultured in 100 mm dish
were infected with control and TF adenovirus [34] (10 moi/cell).
Two days post-infection, cells were washed with buffer A (10 mM
Hepes, 0.15 M NaCl, 4 mM KCl, 11 mM glucose, pH 7.5), and
then treated with calcium ionomycin (10 mM) in buffer B (buffer A
containing 5 mM CaCl2 and 1 mg/ml bovine serum albumin) for
20 min at 37uC. Supernatant was collected and centrifuged first at
2006g for 5 min to remove any cell debris, and then centrifuged
for 1 h at 20,0006g at 4uC to sediment microparticles. Micro-
particle pellet was washed once with buffer A, resuspended in
100 ml of buffer A, and stored at 4uC until used. Characterization
of microparticles derived from endothelial cells transfected with
control adenovirus (TF2 microparticles) and TF adenovirus (TF+
microparticles) in prothrombin activation assay revealed that their
prothrombin activation potential was essentially equal, indicating
that both TF2 and TF+ MPs express equal amounts of
phosphatidylserine. As expected, TF+ microparticles and not
TF2 microparticles effectively activated FX. TF concentration in
TF+ microparticles was estimated in factor X activation assay
using known concentrations of relipidated TF as a standard.
FVIIa antigen and activity assays
rFVIIa antigen levels were determined by ELISA using rabbit
anti-human FVIIa as the capture antibody and biotinylated rabbit
anti-human FVIIa as the detecting antibody. FVIIa clotting
activity was measured in a FVIIa-specific clotting assay as
described previously [25] using STart coagulation analyzer
(Diagnostica Stago, Parsippany, NJ, USA). Briefly, 50 ml of sample
was incubated with 50 ml of 100 nM soluble TF in 1 mM
phospholipids (40% phosphatidyl choline/25% phosphatidyl
serine/35% phosphatidyl ethanolamine) and 100 ml of FVII-
deficient plasma (George King Biomedical Inc., Overland Park,
KS, USA) for 3 min at 37uC, and clotting was initiated by the
addition of 100 ml of 25 mM CaCl2. Varying known concentra-
tions of rFVIIa (0.5 ng to 30 ng/ml for the ELISA; 0.25 to 50 ng/
ml for the activity assay) were used to construct a standard curve.
Measurement of FVIIa-AT complexes
Majority of experiments described in this study required the
measurement of human rFVIIa-mouse AT complex. The amount
of rFVIIa-AT complex generated in our experimental system was
determined by using an in-house developed ELISA, which is
specific to measure the complex between human rFVIIa and
mouse AT. Briefly, rabbit anti-human FVIIa antibodies (5 mg/ml)
were coated onto 96-well ELISA plate for overnight at 4uC. After
blocking the wells with 0.1% gelatin, diluted samples were added
to the wells to capture rFVIIa. After 1 h incubation at room
temperature, unbound material was removed, wells were washed 4
times, and then sheep anti–mouse AT antibody (5 mg/ml) was
added to the wells for 1 h, followed by donkey anti-sheep
biotinylated IgG (1:500), and streptavidin ALP (1:200 dilution)
for 1 h each with ample washings of the wells prior to the addition
of each reagent. Color was developed by using BluePhos microwell
phosphatase substrate system, and measured at 650 nm. A
background reading obtained in a zero min time point sample
was subtracted from the readings of other time points. To generate
rFVIIa-AT standard, a known concentration of rFVIIa (100 nM,
5 mg/ml) was incubated with soluble TF (200 nM), mouse AT
(1 mM), and heparin (10 U/ml) overnight at 37uC, and the
samples were subjected to non-reducing SDS-PAGE followed by
immunoblot analysis to evaluate the extent of FVIIa-AT complex
formation. The concentration of rFVIIa-AT in the standard was
determined by the relative band intensities of rFVIIa-AT and free
rFVIIa. Typically, more than 80% of FVIIa was in complex with
AT. Varying concentrations of rFVIIa-AT complex (0.325 to
80 ng/ml, FVIIa-AT concentration depicts ng FVIIa in complex
with AT) were used to generate a standard curve. The lower
detection limit of the assay was between 0.25 to 0.5 ng ml21
rFVIIa-AT complexes. The assay was specific to detect human
FVIIa-mouse AT complex (substitution of free human FVIIa,
mouse FVIIa, mouse AT or mouse control plasma in place of
human FVIIa-mouse AT complex gave a reading similar to that of
the blank (buffer), OD,0.1).
A similar procedure was used for measuring mouse FVIIa-
mouse AT complexes or human FVIIa-human AT complexes. For
this, ELISA plates were coated with either rabbit anti-mouse
FVIIa antibodies or anti-human FVIIa antibodies to capture
FVII/FVIIa from that particular species. The species-specific
FVIIa-AT complexes were detected using either sheep anti-mouse
AT or anti-human AT. It may be pertinent to note here that anti-
mouse FVIIa antibodies do not cross react with human FVIIa and
vice versa. Mouse FVIIa-AT standard was made by complexing
recombinant mouse rFVIIa with mouse AT, and human FVIIa-
AT standard was made by incubating human rFVIIa with human
AT as described in the above paragraph.
Statistics
All in vitro and ex vivo experiments were repeated three or
more times. For in vivo studies, 3 to 9 mice were used for each
group. Analysis of a data set using statistical software (GraphPad,
Prism vs. 4.03, La Jolla, CA, USA) where n was 8 or more passed
the normality test (D’Agostino and Pearson omni bus normality
test). The data were shown as the mean 6 SEM. Statistical
significance between the two experimental groups was determined
by Students t-test. One-way analysis of variance was used to
determine statistical significance among three groups.
Results
Formation of FVIIa-AT complex in buffer, plasma and
blood
First, we compared the rate of rFVIIa-AT complex formation in
buffer, plasma, and blood in the absence of exogenously added
heparin or TF. We included the plasma concentration of AT in a
buffer system, and rFVIIa (1 mg/ml) was added to all three
systems. As shown in Fig. 1A, increasing amounts of rFVIIa-AT
complex was formed with increase in times under all experimental
conditions. However, only less than 1% of FVIIa was found to be
in complex with AT in a buffer system at the end of 1 h incubation
with AT (Fig. 1A). The rate of rFVIIa-AT complex formation was
significantly higher in plasma compared in buffer (about 4-fold).
The rate of rFVIIa-AT complex formation was 2-fold higher in
blood, compared in plasma.
It is possible that increased levels of rFVIIa-AT generated in
plasma and blood, compared to a buffer system, may be due to the
presence of traces of TF in plasma and blood. To investigate this
possibility, we first attempted to measure TF antigen levels in
mouse plasma. However, the sensitivity of TF ELISA assay was
not suitable for detecting picograms of TF that may be present in
plasma. Next, we measured MP-associated TF activity in plasma
in factor X activation assay, using known concentrations of
relipidated TF as the standard. This assay revealed that plasma of
wild-type mice contains ,2 pg/ml TF (data not shown). Actual
concentration of TF in plasma may be slightly higher since this
assay does not take into account soluble TF and TF that may not
associate with MPs. To determine the role of trace amounts of TF
in plasma in rFVIIa inactivation by AT, first we attempted to
Antithrombin Inactivation of Factor VIIa
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Figure 1. Comparison of FVIIa-AT complex formation in vitro and ex vivo conditions. (A) Blood from wild-type mice was drawn into
rivaroxaban as an anticoagulant. Plasma was separated by centrifugation at 6,0006g for 5 min. To a reaction system not containing plasma or blood,
a plasma concentration of AT (125 mg/ml) was added to Tris-buffered saline (TBS) containing 1 mg/ml bovine serum albumin (BSA), 5 mM CaCl2 and
1 mM MgCl2. rFVIIa was added to all three reaction systems (buffer, plasma and blood) to a final concentration of 1 mg/ml. At various time points, an
aliquot was removed from the reaction mixtures and diluted 1:10 in TBS/BSA containing 10 mM EDTA, and frozen immediately until they were used
for the assay. Levels of FVIIa-AT complex was measured in an ELISA as described in Methods (n = 6 to 9). (B) Plasma obtained from HTF and low TF
mice was divided into two equal aliquots, and one of the aliquots was subjected to centrifugation 20,0006g for 1 h at 4uC to remove microparticles.
rFVIIa (1 mg/ml) was added to both the plasmas, and FVIIa-AT complex generated at 60 min was determined. (C) rFVIIa (1 mg/ml) was incubated for
varying times with AT (125 mg/ml) in TBS/BSA buffer containing 5 mM CaCl2+1 mM MgCl2 in the presence or absence of heparin (1 U/ml) and
relipidated TF (100 pg/ml). FVIIa-AT levels were determined in an ELISA (n = 4). The concentration of FVIIa-AT (ng/ml) reflects ng of FVIIa complexed
with AT. *Indicates that the compared values differ in statistically significant manner (P,0.05).
doi:10.1371/journal.pone.0103505.g001
Antithrombin Inactivation of Factor VIIa
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inhibit plasma TF activity by using TF neutralizing antibodies.
However, both TF antibodies and control IgG interfered in
measuring FVIIa-AT complex levels in an ELISA. Therefore, next
we compared the generation of rFVIIa-AT complexes in plasma of
low TF and HTF mice. As shown in Fig. 1B, the formation of
rFVIIa-AT complex in plasma of HTF mice was significantly
higher than in plasma of low TF mice. Furthermore, removal of
MPs from the plasma by centrifugation significantly reduced the
levels of rFVIIa-AT formation in plasma. These data indicate that
traces of TF in plasma significantly accelerate inactivation of
FVIIa by AT.
The effect of low concentrations of TF on FVIIa-AT complex
formation was examined further in a buffer system where rFVIIa
was incubated with AT 6 heparin (1 U/mL) in the presence or
absence of relipidated TF (100 pg/ml). As shown in Fig. 1C, a low
concentration of TF substantially enhanced the formation of
FVIIa-AT complex both in the absence and presence of heparin.
In the presence of both TF and heparin, we observed ,10-fold
increase in the rate of FVIIa-AT generation in comparison to a
buffer system containing AT alone. However, even in the presence
of heparin and TF, only less than 10% of rFVIIa was found to be
in complex with AT at the end of 60 min incubation time
(Fig. 1C).
In additional studies, to examine the role of MPs on FVIIa-AT
complex formation in plasma, endothelial cell-derived MPs
bearing TF or lacking TF were added to human plasma or whole
blood supplemented with rFVIIa (1 mg/ml), and the levels of
FVIIa-AT formed at the end of 1 h was measured. The
concentration of MP TF chosen for this study was 30 pg/ml, an
outer limit of MP-TF concentration that could possibly be present
in patients with high thrombotic risk (see rev [35] for references).
Although we found a modest, 20 and 50%, increase in FVIIa-AT
levels in plasma supplemented with TF2 and TF+ MPs,
respectively, over the control plasma, this increase was not
statistically significant (FVIIa-AT levels, ng/ml : no MPs,
6.1461.45; TF2 MPs, 8.2362.84; TF+ MPs, 11.1365.9; n = 6).
Heparin (1 U/ml) increased FVIIa-AT levels in plasma by 4-fold,
but the presence of TF2 or TF+ MPs had no measurable influence
on AT inactivation of FVIIa. Similarly, no differences were found
in FVIIa-AT levels in whole blood in the presence or absence of
MPs (data not shown).
Role of TF in generation of FVIIa-AT complex in vivo
First to determine the extent of FVIIa-AT complex formed
in vivo in mice under basal conditions and the role of TF in
generation of FVIIa-AT, we measured mouse FVIIa-AT com-
plexes in plasma obtained from wild-type, HTF and low TF mice.
Both wild-type and HTF mice contained similar levels of mouse
FVIIa-AT complex (wild-type, 6.9362.47 ng/ml, n = 6; HTF,
7.6662.40 ng/ml, n = 8) whereas FVIIa-AT levels were substan-
tially low in low TF mice (1.2160.19 ng/ml, n = 12).
Next to compare the rate of AT inactivation of FVIIa in vivo vs.
in vitro or ex vivo, and to determine the role of TF or other
in vivo parameters in influencing AT inactivation of therapeutic
concentrations of rFVIIa, low TF and HTF mice were adminis-
tered with human rFVIIa (120 mg kg21 body weight). Blood was
collected at various time intervals following rFVIIa administration,
and rFVIIa-AT complex and rFVIIa antigen levels in plasma were
measured. As shown in Fig. 2A, rFVIIa complex formation with
AT was evident as early as 1 min following rFVIIa administration
in both the genotypes. rFVIIa-AT levels peaked at 60 min, and
start to decline thereafter. At 24 h following rFVIIa administra-
tion, rFVIIa-AT complexes were barely detectable in plasma. The
levels of rFVIIa-AT complex were significantly higher in HTF
mice as compared with low TF mice at 30 and 60 min following
rFVIIa administration (Fig. 2A). It may be pertinent to note here
that measurement of TAT at these points showed no significant
differences between HTF and low TF mice (TAT levels ng/ml at
30 min: low TF, 19.6964.38; HTF 14.3062.7; at 60 min: low
TF, 24.2769.78; HTF 18.9364.7, n = 6).
We also measured rFVIIa antigen levels in the plasma of HTF
and low TF mice to investigate whether TF influences pharma-
cokinetics of rFVIIa, which in turn could influence the formation
of rFVIIa-AT complex in vivo. As shown in Fig. 2B, no significant
differences were found in rFVIIa antigen levels in the HTF and
low TF mice, indicating that differences in rFVIIa-AT complex
levels in these mice at 30 and 60 min is not due to the difference in
the plasma rFVIIa antigen levels in these mice.
The comparison of rFVIIa antigen and rFVIIa-AT complex
levels, particularly in samples obtained at 60 min or later following
rFVIIa administration, suggests that rFVIIa antigen assay does not
fully recognize rFVIIa in rFVIIa-AT complex. Thus, rFVIIa
antigen levels were substantially lower than rFVIIa-AT complex
levels at these later time points, and also lower than predicted
rFVIIa antigens levels based on our earlier FVIIa clearance studies
utilizing 125I-labeled rFVIIa. Here, it may be pertinent to note that
we evaluated several other FVIIa antibodies, both prepared in-
house and obtained commercially or from other investigators, and
none of the antibodies recognized rFVIIa in complex with AT to
the same extent as of free rFVIIa.
Role of EPCR in generation of FVIIa-AT complex in vivo
Recently, we have shown that FVIIa binds EPCR both in vitro
and in vivo [19,36]. Therefore, we investigated here whether
FVIIa binding to EPCR influences FVIIa-AT complex formation
in vivo. Human rFVIIa was injected into wild-type, EPCR over-
expressing (EPCR-OE), and EPCR-deficient mice (EPCR-def) and
the levels of rFVIIa-AT complex were measured. As shown in
Fig. 3A, there were no significant differences in the levels of
rFVIIa-AT complex generated among the wild-type, EPCR-def
and EPCR-OE mice. We also measured endogenous FVIIa-AT
levels in the above groups of mice (no rFVIIa was administered).
These data also showed no significant differences in FVIIa-AT
levels among the three groups (Fig. 3B). It may pertinent to note
here that while human FVIIa binds murine EPCR, murine FVIIa
does not bind murine EPCR in any significant manner [36].
Effect of enhanced TF expression on FVIIa-AT complex
formation in vivo
If traces of TF contribute to the generation of FVIIa-AT
complex formation in vivo, then pathological conditions (e.g.,
sepsis, atherosclerosis etc.), where TF expression is upregulated in
cells that come in contact with blood, may accelerate FVIIa-AT
complex formation. Wang et al. [33] showed that TF MP levels
were increased several fold in endotoxemic mice. To test the effect
of increased expression of TF in vivo on FVIIa-AT generation,
wild-type mice were injected with saline or LPS (5 mg/kg body
weight), and 5 h after LPS administration blood was collected
from these mice by cardiac puncture, and plasma was processed
for measuring MPs procoagulant activity and mouse FVIIa-AT
complexes. As shown in Fig. 4A, LPS administration markedly
increased the procoagulant activity of plasma MPs. The increased
procoagulant activity was due to the generation of TF+ MPs since
the incubation of MPs with mouse TF mAb blocked the increased
procoagulant activity. LPS administration increased the levels of
FVIIa-AT complexes in plasma by about 50% compared to the
saline control, but the difference is not statistically significant,
probably due to a wider variation in FVIIa-AT levels in these
Antithrombin Inactivation of Factor VIIa
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mice. It may be important to note here that measuring
endogenous murine FVIIa-AT complexes in LPS administered
mice may not provide a complete picture of the role of TF on AT
inactivation of FVIIa since FVIIa-AT complex formation is
limited by the availability of FVIIa. LPS administration may not
significantly increase FVIIa levels in vivo [37].
Therefore, to investigate the effect of enhanced in vivo TF on
AT inactivation of FVIIa more accurately, HTF mice were
injected with LPS (5 mg/kg body weight), and after 5 h, human
rFVIIa was given to these mice via tail vein injection, and the
amount of rFVIIa-AT complex generated in plasma was
measured. As shown in Fig. 5A, MP TF activity was increased
by 6-fold in HTF mice administered with LPS compared to
control HTF mice. Measurement of rFVIIa-AT complex in these
mice showed a slight but statistically significant increase in rFVIIa-
AT levels in LPS-challenged mice compared to control mice
(Fig. 5B). We also measured the levels of endogenous mouse
FVIIa-AT complexes generated in the above experimental system.
LPS treatment increased the levels of endogenous mouse FVIIa-
AT in these mice by 40% (data not shown).
Role of TF in retention of rFVIIa activity and antigen
in vivo
Recently, we have shown that rFVIIa entered into extravascular
tissues via EPCR-dependent mechanism is retained in tissues for
extended time periods [25]. It has been thought that TF present
on extravascular cells may play a role in retention of FVIIa in
tissues [25]. Our earlier analysis of TF expression by immunohis-
Figure 2. Levels of FVIIa-AT generated in vivo in HTF and low TF mice following administration of rFVIIa. HTF and low TF mice were
injected with rFVIIa (120 mg/kg body weight) intravenously via the tail vein. FVIIa-AT complex (A) and FVIIa antigen (B) levels were determined in
plasma obtained from these mice at various time points following rFVIIa administration (n = 4 or more). The small bar (2) in the figure represents
expected FVIIa antigen levels, based on our previous study of rFVIIa clearance in wild-type mice using 125I-rFVIIa as a tracer [26], at 3, 5, 15, 30, 60, 120,
180, and 240 min following rFVIIa administration. The concentration of FVIIa-AT (ng/ml) reflects ng of FVIIa complexed with AT. *Indicates the value
differs in statistically significant manner (P,0.05) between HTF and low TF mice at the given time point.
doi:10.1371/journal.pone.0103505.g002
Figure 3. Levels of FVIIa-AT generated in vivo in wild-type,
EPCR-overexpressing (EPCR-OE), and EPCR-deficient (EPCR-
def) mice. (A) Wild-type, EPCR-OE and EPCR-def mice were injected
with rFVIIa (120 mg/kg body weight) intravenously via the tail vein.
FVIIa-AT levels in plasma obtained from these mice at 60 min post-
rFVIIa administration was measured in an ELISA assay (n = 3–4). (B)
Endogenous FVIIa-AT levels. Plasma obtained from wild-type, EPCR-OE
and EPCR-def mice that were not subjected to any treatment were used
to measure endogenous FVIIa-AT levels. The concentration of FVIIa-AT
(ng/ml) reflects ng of FVIIa complexed with AT. ns, not statistically
significant as determined in one-way analysis of variance.
doi:10.1371/journal.pone.0103505.g003
Figure 4. Measurement of microparticle TF procoagulant
activity and FVIIa-AT levels in plasma following LPS adminis-
tration in wild-type mice. Wild-type mice (C57BL/6J) were injected
with saline or LPS (5 mg/kg body weight) intraperitoneally. 5 h after
saline or LPS administration, blood was obtained from these mice by
cardiac puncture, and plasma samples were processed for isolation of
microparticles to measure TF procoagulant activity (A) or for
determination of FVIIa-AT levels (B). Procoagulant activity measured
in factor Xa generation assay in the absence or presence of mouse TF
mAb (10 mg/ml, preincubated for 30 min) (n = 5). *Indicates the values
differ in statistically significant manner between the control and LPS-
treated mice. The concentration of FVIIa-AT (ng/ml) reflects ng of FVIIa
complexed with AT. *, P,0.05; ***, P,0.001; ns, not statistically
significant.
doi:10.1371/journal.pone.0103505.g004
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tochemistry in various tissues of wild-type mice revealed the
presence of TF in bone joints in the zone of calcified cartilage in
the growth plate region and the mineralized bone [38]. To
investigate the effect of TF in retaining FVIIa in bone joints,
rFVIIa was administered to low TF and HTF mice, and seven
days after rFVIIa administration, bone joints from these mice were
collected, and rFVIIa antigen and activity levels in bone joints
were measured. As shown in Fig. 6A, rFVIIa antigen levels were
significantly higher in the bone joints of HTF mice as compared
with low TF mice. Measurement of FVIIa activity in these samples
showed that rFVIIa in the bone joint of HTF is functionally active.
As with rFVIIa antigen level, FVIIa activity level was substantially
higher in bone joints of HTF as compared to low TF mice
(Fig. 6B).
Discussion
The present study carried out with low TF mice expressing
,1% of wild-type TF and HTF mice expressing ,100% of wild-
type TF indicates that TF contributes to the formation of FVIIa-
AT complex in vivo. Increased levels of FVIIa-AT complex were
found in plasma of HTF mice compared to low TF mice
endogenously as well as after administration of a therapeutic
concentration of rFVIIa. Further, the observation that increased
intravascular exposure of TF by LPS administration to HTF mice
moderately, but statistically significant fashion, increased FVIIa-
AT levels in the plasma confirms that increased FVIIa-AT levels in
plasma may reflect exposure of blood to increased levels of
intravascular TF. Nonetheless, our data also indicate that the
effect of TF on AT inactivation of FVIIa appears to be modest,
and therefore, measurement of FVIIa-AT levels in plasma may not
be a very sensitive indicator of intravascular TF exposure, and
may lack robustness in accurately predicting hypercoagulable
state. For example, despite a ,100-fold difference in TF
expression between HTF and low TF mice, differences in
FVIIa-AT levels between the two genotypes following rFVIIa
administration was less than 2-fold, that too only at 30 and 60 min
following rFVIIa administration but not at later time points.
Similarly, LPS administration increased MP-associated TF activity
in plasma of HTF mice by more than 600% whereas it only led to
a small increase (,25%) in FVIIa-AT levels in plasma.
Recent studies of pharmacokinetics of rFVIIa in hemophilia
patients or animals showed that the majority of rFVIIa clotting
activity following rFVIIa intravenous administration was inhibited
by AT by forming rFVIIa-AT complexes [11,39,40]. These results
suggest that AT inhibition of rFVIIa controls drug duration in
hemophilia treatment with rFVIIa. Furthermore, these data also
showed that the rate of inhibition of rFVIIa by AT is significantly
higher in vivo than in vitro [40]. Consistent with these data, we
found that most of rFVIIa in circulation was in complex with AT
at 60 min following rFVIIa administration as the levels of FVIIa-
AT complex measured at this time were very similar to total FVIIa
antigen levels in the circulation (compare Fig. 2A and 2B).
Although TF contributes to the formation of rFVIIa-AT complex
in vivo, it does not appear to influence the overall pharmacoki-
netics of rFVIIa as rFVIIa was cleared in a similar fashion in low
TF and HTF mice. These data were also consistent with the
earlier observation that showed clearance of FVIIa was unaffected
Figure 5. Effect of increased TF expression on formation of FVIIa-AT complex in HTF mice administered with therapeutic
concentrations of rFVIIa. HTF mice were injected with LPS (5 mg/kg body weight) intraperitoneally. 5 h after LPS administration, rFVIIa (120 mg/kg
body weight) was injected into these mice as well as unchallenged mice. 1 h following rFVIIa administration, blood was drawn from these mice by
cardiac puncture, and plasma samples were processed for isolation of TF microparticles or determination of FVIIa-AT levels. (A) Microparticle TF
activity; (B) FVIIa-AT levels (n = 4). The concentration of FVIIa-AT (ng/ml) reflects ng of FVIIa complexed with AT. *Indicates the values differ in
statistically significant manner between the control and LPS-treated mice.
doi:10.1371/journal.pone.0103505.g005
Figure 6. Higher levels of FVIIa retained in bone joints of HTF compared to low TF mice. HTF and low TF mice were injected intravenously
via the tail vein with rFVIIa (120 mg/kg body weight). Seven days later, bone joints were collected, bone joint fluids were eluted, and assayed for FVIIa
antigen (A) and FVIIa activity (B) levels (n = 3). *Indicates the value differs in statistically significant manner (P,0.05) between HTF and low TF mice.
doi:10.1371/journal.pone.0103505.g006
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by its inactivation with AT [41]. The observation that rFVIIa-AT
complex formation was impeded, but not markedly impaired in
low TF mice indicates that TF plays probably a minor role in
FVIIa inactivation by AT in vivo. Overall, our data suggest that
although TF contributes to FVIIa-AT generation in vivo, it may
not be the principle player that regulate rFVIIa inactivation by AT
in vivo.
Comparison of rFVIIa-AT complex formation in vitro, ex vivo
and in vivo conditions show that only traces of rFVIIa was
complexed with AT in vitro (in buffer) in the absence of heparin.
Although rFVIIa-AT complex formation was higher in plasma
and blood, relative to that in buffer, still only less than 10% of
rFVIIa formed complex with AT even after 1 h of incubation
time. A significantly higher level of rFVIIa-AT formation in blood,
compared to plasma, indicates that blood cells may promote
rFVIIa inactivation by AT. At present, blood cell types that are
responsible for this are unknown. Addition of heparin and a low
concentration of relipidated TF increased FVIIa-AT formation in
a buffer system, reaching to comparable level obtained in the
blood in ex vivo condition. At present, it is unclear whether
heparin-like proteoglycans and/or TF on blood cells is responsible
for increasing FVIIa-AT complex formation in blood. It may be
pertinent to add here that exogenous addition of TF+ MPs to
human slightly increased AT inactivation of FVIIa in ex vivo, but
this increase was not statistically significant. It is possible that other
clotting factors in blood or other components of blood may
contribute for the increased FVIIa-AT generation in blood. Here,
one should note that both clotting factors IX and X were shown to
enhance the inhibition of FVIIa-TF by AT on a human bladder
carcinoma cell line [42]. In contrast to in vitro and ex vivo, rFVIIa
complex formation with AT was relatively rapid in vivo. Within
one minute following rFVIIa administration, the formation of
rFVIIa-AT complex was evident, and most of rFVIIa present in
circulation at 60 min following rFVIIa administration was in
complex with AT. It is unclear at present the exact mechanism(s)
by which FVIIa was rapidly inactivated by AT in vivo.
Recently, we have shown that rFVIIa administered to mice
rapidly associates with EPCR on vascular endothelium in vivo
[25,26,36]. Therefore, it is entirely possible that FVIIa binding to
EPCR could facilitate FVIIa inactivation by AT. However, studies
conducted herein with EPCR-deficient mice and EPCR overex-
pressing mice (at least 8- or more fold higher EPCR expression
over the wild-type [32]) clearly show that EPCR does not play a
role in FVIIa-AT complex formation in vivo as we observed
similar levels of rFVIIa-AT complex in these mice following
rFVIIa administration.
Our recent studies showed that although most of the rFVIIa
administered to mice was cleared rapidly from circulation with a
half-life of less than 30 min, a small amount of rFVIIa enters into
extravascular tissues, and this FVIIa was retained for extended
time periods in tissues [25,26,38,43]. Since most of the extravas-
cular cells express TF, and FVIIa binds to TF with a high affinity,
it had been thought that TF may be playing a role in retaining
FVIIa entered into extravasculature [25]. Our present observation
of increased levels of rFVIIa activity and antigen in bone joints of
HTF mice compared to low TF mice even 7 days after rFVIIa
administration clearly supports the above hypothesis that FVIIa
entered into extravasculature associates with TF, and this
association could retain FVIIa for extended time periods in
extravascular tissues. The potential significance of this finding to
hemostasis and hemophilia therapy with rFVIIa had been
discussed earlier [25].
In summary, data presented in the manuscript show that TF
contributes to FVIIa-AT complex formation in vivo. However,
presence of traces of intravascular TF alone cannot explain the
generation of high levels of FVIIa-AT complex rapidly in vivo
following rFVIIa administration. EPCR does not influence FVIIa-
AT complex formation in vivo. Finally, our data also show that
TF plays a role in retaining FVIIa entered into extravasculature.
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